Jefferies Upgrades Gland Pharma Hold Amid Recovery Signs, Goldman Maintains Sell

Jefferies upgraded Gland Pharma to Hold with a target price of ₹1,970, citing operational recovery and improved capacity at its European subsidiary Cenexi, despite weakness in the US segment and limited upside potential at current valuations. Contrarily, Goldman Sachs maintains a Sell rating with a ₹1,675 target, acknowledging margin improvements but projecting muted growth and weakness in the US business. Dow Inc. received an upgrade from Rothschild & Co Redburn from Neutral to Buy, with a lowered price target of $40, based on expected polyethylene margin recovery and strategic capital allocation including potential debt repayment and stock buybacks, despite ongoing financial challenges. Quantum BioPharma, a micro-cap biopharma focused on neurodegenerative and inflammatory diseases, has gained 166% over the past year thanks to pipeline progress, regulatory advances, and strategic investments, highlighting its high-risk, high-reward profile. BioCryst Pharmaceuticals (BCRX) earned a Buy rating from Needham and RBC Capital due to strong sales growth of its key product Orladeyo, rising prescriptions, and strategic positioning in the rare disease sector despite recent leadership changes, with price targets of $17 and $13 respectively.